Evaluation of ricin A-chain immunotoxins directed against human T cells☆
References (46)
- et al.
Blood
(1985) - et al.
Lancet
(1984) - et al.
Blood
(1983) - et al.
Blood
(1985) - et al.
Blood
(1985) - et al.
Blood
(1984) - et al.
Blood
(1985) - et al.
Immunochemistry
(1978) - et al.
Virology
(1979) - et al.
J. Immunol. Methods
(1981)
Blood
(1985)
Blood
(1985)
Exp. Cell Res
(1985)
Cell
(1980)
Mol. Immunol
(1984)
Cell
(1980)
Cell
(1984)
Cell
(1980)
J. Ultrastruc. Res
(1975)
Immunol. Rev
(1982)
Science
(1983)
J. Immunol
(1984)
Immunol. Rev
(1982)
Cited by (79)
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
2009, Leukemia ResearchCitation Excerpt :Furthermore, the inclusion of anti-CD19 might impact the rate of entry of DT to critical cell organelles such as lysosomes or ER. For example, earlier studies showed that different IT ligands (such as CD2, CD5, and CD3) affected the rate of entry of IT into the lysosomal compartment [38]. Creating bispecific IT may be a means to improve IT internalization and trafficking.
Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli
2005, Protein Expression and PurificationConstruction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line
2004, International ImmunopharmacologyAntibodies for targeted gene therapy: Extracellular gene targeting and intracellular expression
1998, Advanced Drug Delivery Reviews
- ☆
Supported by American Cancer Society Institutional Grant Award IN-26Z, NIH Grants CA-28149, CA-18029, and AG-04360, and Contract N0014-82-K0660 from the Office of Naval Research, Department of Defense.
- 1
Dr. Press is the recipient of a Clinical Oncology Career Development Award (85-35) from the American Cancer Society.
Copyright © 1986 Published by Elsevier Inc.